[1]
|
Tanboon, J. and Nishino, I. (2022) Update on Dermatomyositis. Current Opinion in Neurology, 35, 611-621.
https://doi.org/10.1097/WCO.0000000000001091
|
[2]
|
Constante, M., Barradas, A., Esteves, A., Pereira, S. and Silva, L. (2022) Dermatomyositis: A Cancer Red Flag. Cureus, 14, e32502. https://doi.org/10.7759/cureus.32502
|
[3]
|
李筱筱, 李雨薇, 孙莉, 等. 特发性炎性肌病不同亚型临床特征、肌炎抗体谱、肌电图的差异性表现[J]. 疑难病杂志, 2023, 22(5) :515-519.
|
[4]
|
D’Silva, K., Li, L., Lu, N., Ogdie, A., Avina-Zubieta, J. and Choi, H. (2021) Persistent Premature Mortality Gap in Dermatomyositis and Polymyositis: A United Kingdom General Population-Based Cohort Study. Rheumatology, 60, 2653-2660. https://doi.org/10.1093/rheumatology/keaa661
|
[5]
|
Osaki, M., Tachikawa, R., Ohira, J., Hara, S. and Tomii, K. (2021) Anti-Transcriptional Intermediary Factor 1-γ Antibody-Positive Dermatomyositis Induced by Nivolumab for Lung Adenocarcinoma: A Case Report. Investigational New Drugs, 39, 251-255. https://doi.org/10.1007/s10637-020-00974-7
|
[6]
|
谭艳平, 刘志刚. 皮肌炎/多发性肌炎病因及发病机制的研究进展[J]. 中国皮肤性病学杂志, 2016, 30(6): 634-636, 649.
|
[7]
|
DeWane, M., Waldman, R. and Lu, J. (2020) Der-matomyositis: Clinical Features and Pathogenesis. Journal of the American Academy of Dermatology, 82, 267-281. https://doi.org/10.1016/j.jaad.2019.06.1309
|
[8]
|
Megremis, S., Walker, T., He, X., O’Sullivan, J., Ollier, W., Chi-noy, H., et al. (2021) Analysis of Human Total Antibody Repertoires in TIF1γ Autoantibody Positive Dermatomyositis. Communications Biology, 4, Article No. 419.
https://doi.org/10.1038/s42003-021-01932-6
|
[9]
|
周娅丽, 胥璟, 杨静, 等. 皮肌炎107例患者肌电图与临床特征的回顾性分析[J]. 临床皮肤科杂志, 2022, 51(11): 644-647. https://doi.org/10.16761/j.cnki.1000-4963.2022.11.002
|
[10]
|
Kim, N., Nam, E., Kang, J., Song, H., Im, C. and Kang, Y. (2014) Complex Repetitive Discharge on Electromyography as a Risk Factor for Malignancy in Idiopathic In-flammatory Myopathy. The Korean Journal of Internal Medicine, 29, 814-821. https://doi.org/10.3904/kjim.2014.29.6.814
|
[11]
|
Spalkit, S., Sinha, A., Prakash, M. and Sandhu, M. (2021) Der-matomyositis: Patterns of MRI Findings in Muscles, Fascia and Skin of Pelvis and Thigh. European Journal of Radiol-ogy, 141, Article ID: 109812.
https://doi.org/10.1016/j.ejrad.2021.109812
|
[12]
|
Ashton, C., Paramalingam, S., Stevenson, B., Brusch, A. and Needham, M. (2021) Idiopathic Inflammatory Myopathies: A Review. Internal Medicine Journal, 51, 845-852. https://doi.org/10.1111/imj.15358
|
[13]
|
Chua, C., Low, J., Lim, W. and Manghani, M. (2022) Characteristics of Anti-Transcriptional Intermediary Factor 1 γ Autoantibody-Positive Dermatomyositis Patients in Singapore. Annals of the Academy of Medicine of Singapore, 51, 755-765. https://doi.org/10.47102/annals-acadmedsg.2022278
|
[14]
|
Dani, L., Holmqvist, M., MartÍNez, M., Tral-lero-Araguas, E., Dastmalchi, M., Svensson, J., et al. (2020) Anti-Transcriptional Intermediary Factor 1 γ Antibodies in Cancer-Associated Myositis: A Longitudinal Study. Clinical and Experimental Rheumatology, 38, 67-73.
|
[15]
|
Solimena, M., Folli, F., Denis-Donini, S., Comi, G., Pozza, G., De, Camilli, P., et al. (1988) Autoantibodies to Glutamic Acid De-carboxylase in a Patient with Stiff-Man Syndrome, Epilepsy, and Type I Diabetes Mellitus. The New England Journal of Medicine, 318, 1012-1020. https://doi.org/10.1056/NEJM198804213181602
|
[16]
|
Baizabal-Carvallo, J. (2019) The Neurological Syndromes Associated with Glutamic Acid Decarboxylase Antibodies. Journal of Autoimmun-ity, 101, 35-47. https://doi.org/10.1016/j.jaut.2019.04.007
|
[17]
|
Dade, M., Berzero, G., Izquierdo, C., Giry, M., Benazra, M., Delattre, J., et al. (2020) Neurological Syndromes Associated with Anti-GAD Antibodies. International Journal of Molecular Sciences, 21, Article 3701.
https://doi.org/10.3390/ijms21103701
|
[18]
|
Daif, A., Lukas, R., Issa, N., Javed, A., VanHaerents, S., Reder, A., et al. (2018) Antiglutamic Acid Decarboxylase 65 (GAD65) Antibody-Associated Epilepsy. Epilepsy and Behavior, 80, 331-336.
https://doi.org/10.1016/j.yebeh.2018.01.021
|
[19]
|
Hoesly, P., Sluzevich, J., Jambusaria-Pahlajani, A., Lesser, E., Heckman, M. and Abril, A. (2019) Association of Antinuclear Antibody Status with Clinical Features and Malignancy Risk in Adult-Onset Dermatomyositis. Journal of the American Academy of Dermatology, 80, 1364-1370. https://doi.org/10.1016/j.jaad.2018.11.023
|
[20]
|
Ceribelli, A., Isailovic, N., De, Santis, M., Generali, E., Fredi, M., Cavazzana, I., et al. (2017) Myositis-Specific Autoantibodies and Their Association with Malignancy in Italian Patients with Polymyositis and Dermatomyositis. Clinical Rheumatology, 36, 469-475. https://doi.org/10.1007/s10067-016-3453-0
|
[21]
|
高颖, 黄瑶, 侯彦波, 等. 抗谷氨酸脱羧酶65抗体阳性相关中枢神经系统病变临床特点分析[J]. 中风与神经疾病杂志, 2022, 39(7) : 647-649. https://doi.org/10.19845/j.cnki.zfysjjbzz.2022.0164
|
[22]
|
邱占东, 刘峥, 李大伟, 等. 多重抗神经元抗体阳性的神经系统副肿瘤综合征临床分析[J]. 中国神经免疫学和神经病学杂志, 2020, 27(4) : 261-265. https://doi.org/10.3969/j.issn.1006-2963.2020.04.003
|
[23]
|
田春艳, 谷涛, 陈桂生. 多重抗体神经系统副肿瘤综合征临床特征分析[J]. 宁夏医学杂志, 2023, 45(1): 19-21.
https://doi.org/10.13621/j.1001-5949.2023.01.0019
|
[24]
|
Zhen, C., Hou, Y., Zhao, B., Ma, X., Dai, T. and Yan, C. (2022) Efficacy and Safety of Rituximab Treatment in Patients with Idiopathic Inflammatory Myopathies: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 13, Article 1051609. https://doi.org/10.3389/fimmu.2022.1051609
|
[25]
|
Cobos, G., Femia, A. and Vleugels, R. (2020) Dermatomyositis: An Update on Diagnosis and Treatment. American Journal of Clinical Dermatology, 21, 339-353. https://doi.org/10.1007/s40257-020-00502-6
|
[26]
|
Pipitone, N. and Salvarani, C. (2020) Up-To-Date Treatment and Management of Myositis. Current Opinion in Rheumatology, 32, 523-527. https://doi.org/10.1097/BOR.0000000000000745
|
[27]
|
Smith, L. and Paik, J. (2020) Promising and Upcoming Treatments in Myositis. Current Rheumatology Reports, 22, Article No. 65. https://doi.org/10.1007/s11926-020-00943-2
|